Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

HIGHLIGHTS

• who: Sang T. Kim from the Patients and collection of tissue samplesThis study was approved by the institutional review board at The University of Texas MD Anderson Cancer Center (IRB No: PA16-0935). Prior to the procedures (diagnostic arthrocentesis and/or venipuncture), participants provided written informed consent, allowing collection of residual SF and/or PB samples as well as prospective follow-up for , months. We collected residual SF and/or PB from , patients who newly developed arthritis after ICI therapy. As serum-negative controls, we collected PB samples from patients who had not developed irAEs at least . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.